| Ytd | 13.71% | |
| 1y | -24.79% |
| Open | 0.99 | Prev Close | 0.98 | Low | 0.93 | High | 0.99 | Mkt Cap | 43.08M |
| Vol | 174.08K | Avg Vol | 294.05K | EPS | -0.33 | P/E | N/A | Forward P/E | -3.10 |
| Beta | 0.99 | Short Ratio | 3.43 | Inst. Own | 8.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.89 | 200-d Avg | 0.98 | 1yr Est | 5.50 |
RNXT News
Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
The designation was issued by the FDA's Office of Orphan Products Development pursuant to Sectio
Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial
RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 mil
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensu
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates RenovoRx (NASDAQ:RNXT) with a B
The allowed claims of the patent protect the RenovoCath dual-occlusion catheter-based system equippe
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensu
The proceeds from this financing are expected to allow RenovoRx to capitalize on and accelerate its
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company
Ascendiant Capital analyst Edward Woo maintains RenovoRx (NASDAQ:RNXT) with a Buy and raises the
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scie
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensu
First Registry-Eligible Patient Procedure Commenced at the University of Vermont Cancer CenterBaptis
Several biotech stocks are showing renewed strength over the past week, with their Momentum scores s
"At the same time, we are very excited to report that the independent Data Monitoring Committee
RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which beat the analyst consens
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s sessio
Gainers Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of sp
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced n
Gainers
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday af
On Wednesday, 807 companies reached new 52-week lows.
On Monday, 721 companies achieved new lows for the year.
On Friday, 431 companies hit new 52-week lows.